Argenx
ARGX
#549
Rank
NZ$60.41 B
Marketcap
$990.54
Share price
-0.19%
Change (1 day)
54.57%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Earnings for Argenx (ARGX)

Earnings in 2024 (TTM): NZ$0.14 Billion

According to Argenx 's latest financial reports the company's current earnings are NZ$2.19 Billion. , an increase over its 2023 earnings that were of -NZ$0.55 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Argenx from 2013 to 2024

Annual earnings

Year Earnings Change
2024 NZ$0.15 B-127.97%
2023 -NZ$0.55 Billion-58.25%
2022 -NZ$1.32 Billion
2019 -NZ$0.36 Billion124.95%
2018 -NZ$0.16 Billion132.04%
2017 -NZ$68.82 Million54.86%
2016 -NZ$44.45 Million33%
2015 -NZ$33.42 Million13.63%
2014 -NZ$29.41 Million46.25%
2013 -NZ$20.11 Million